Latest Profitability News

Careteq Limited reports strong Q3 FY25 progress with near completion of its 1-System platform integration, revenue growth exceeding forecasts, and new strategic partnerships broadening its healthcare footprint.

4DMedical Limited reports a 103% surge in year-to-date revenue, secures major contracts with leading healthcare providers, and advances its CT:VQ™ technology towards FDA clearance.

Pacific Edge’s Cxbladder Plus and Triage 1 diagnostic tests are set for significant Medicare reimbursement increases, potentially reshaping the company’s US market prospects.

InteliCare Holdings has secured a binding agreement to trial its AI-driven platform at mecwacare’s Trescowthick Centre, marking a significant step in its commercialisation strategy within Victoria’s aged care sector.

Nova Eye Medical reported a 27% rise in Q3FY25 sales excluding China, driven by record US performance and a sharp reduction in glaucoma segment losses. The company confirmed FY25 revenue guidance and unveiled plans to expand its iTrack™ technology into ocular drug delivery.

Hiremii Limited has completed its 2024-25 AI recruitment platform roadmap nine weeks early, with its proprietary AI outperforming industry shortlisting benchmarks. Despite a slight revenue decline due to market slowdowns, the company is poised for growth through technology commercialization and strategic M&A.

QuickFee Limited reported a 29% rise in Q3 FY25 revenue, driven by strong growth in its finance products and Connect platform. However, a significant US credit impairment has prompted a downward revision of its FY25 statutory earnings guidance.

Oliver’s Real Food reported an 18% revenue decline in the March 2025 quarter, impacted by store closures and trading calendar shifts, yet achieved a strong rebound in EBITDA margin to 11.5%.

Resonance Health reports record $14.9M cash receipts over 12 months and completes cost-cutting measures while advancing two major pharma clinical trials on schedule.

ReadCloud reports robust first half FY25 results, driven by a standout 29% revenue increase in its VET-in-Schools segment, alongside positive cash flow and strengthened operating leverage.

Harmoney Corp upgrades its FY25 cash NPAT guidance to $5.5 million, driven by strong loan book growth and improved margins, while announcing a strategic 5% on-market share buy-back.

Harmoney has raised its FY25 cash NPAT guidance to $5.5 million and announced an on-market share buy-back, setting the stage for accelerated loan book growth and improved returns in FY26.